mirumpharma.com (MIRM): Net earnings per share growth forecast for next year

mirumpharma.com (MIRM) - corporate logo

The forward net income growth rate reflects expert expectations, where 91.90 becomes the new value for this metric. Mirum Pharmaceuticals (MIRM) maintains high pricing power and guaranteed insurance payouts due to its monopoly position in the therapy of rare liver pathologies. Growth is driven by the success of Livmarli and the integration of new assets, while business resilience is supported by the medical community's recognition of its treatment methods.

Mirum Pharmaceuticals, Inc. (MIRM): Expected earnings per share growth for next year from 07/04/2022 to 11/16/2026

Mirum Pharma - analytical breakdowns and key metrics (MIRM)

- share price and consensus valuation forecast:
Basic company analysis:MIRM, mirumpharma.com
Core merchandise of Mirum Pharmaceuticals, Inc.

To protect capital amid uncertainty, assessing the annual EPS growth for the next period is critical, as it measures the expected earnings per share dynamics relative to current values. This indicator reflects the ability of Mirum Pharmaceuticals (MIRM) to monetize the success of Livmarli and the integration of new assets, transforming the expansion of therapeutic indications into real growth in shareholder value.